Another study indicated that FOXC1 demethylation, which results in its overexpression, is closely correlated with chemoresistance in locally advanced breast cancer patients receiving neoadjuvant anthracycline treatment [18]. This evidence concerns the gene FOXC1 and breast carcinoma.